DBV Technologies S.A.

Research DBV Technologies S.A. (DBV) on Bullrun: market cap EUR 804.35M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerDBV
• ExchangeF
• CountryFrance
• SectorHealthcare
• IndustryBiotechnology
• CurrencyEUR
• Market capEUR 804.35M
• Financial periodFY2025
• Net income-USD 147.16M

Valuation Snapshot

latest market cap is EUR 804.35M.

About DBV Technologies S.A.

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.

Frequently asked questions

What is DBV Technologies S.A.'s market cap?

DBV Technologies S.A.'s market capitalization is EUR 804.35M.

What does DBV Technologies S.A. do?

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France.